ResultsIQ › Latest results › Amrutanjan Health Care Limited

Amrutanjan Health Care Limited Q4 FY26 results deck summary

NSE: AMRUTANJAN · BSE: 590006

Results deck of 8 May 2026, summarised by AI from the filing.

Added 44K new chemists; new Sanitary Pad plant slated to commence production in May

Key takeaways

Change Added 44K new chemists; new Sanitary Pad plant slated to commence production in May
Risk COGS inflation expected this year from Middle East wars affecting crude prices and supply chains; mitigating by price increases to some extent

Amrutanjan Health Care Limited Q1 FY27 results

As filed: Revenue ₹103 cr (+10% year on year), EBITDA ₹6.3 cr (−31% year on year), PAT ₹4.4 cr (−26% year on year), EBITDA margin 6.1% (−350 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

Q4 FY26: Revenue ₹150 cr (+11% year on year), EBITDA ₹25.6 cr (+42% year on year), PAT ₹16.2 cr (+36% year on year), EBITDA margin 17.1% (+373 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was above it. EBITDA margin rose 373 bps year on year. Share price after the results: +0.6% in 28 days (Nifty 500: −2.8%).
Q3 FY26: Revenue ₹141 cr (+15% year on year), EBITDA ₹25.2 cr (+5% year on year), PAT ₹19.5 cr (+2% year on year), EBITDA margin 17.8% (−167 bps). Score 41 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 167 bps year on year. Share price after the results: −2.1% in 30 days (Nifty 500: −3.2%).
Q2 FY26: Revenue ₹118 cr (+7% year on year), EBITDA ₹17.0 cr (+21% year on year), PAT ₹14.0 cr (+17% year on year), EBITDA margin 14.4% (+168 bps). Score 40 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 168 bps year on year. Revenue rose ₹8.0 cr on a year ago, against ₹11.0 cr the year before. Share price after the results: −7.1% in 30 days (Nifty 500: −0.8%).
Q1 FY26: Revenue ₹94.0 cr (+12% year on year), EBITDA ₹9.0 cr (+125% year on year), PAT ₹8.0 cr (+60% year on year), EBITDA margin 9.6% (+481 bps). Score 59 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 481 bps year on year. Other income 36% of PBT. Revenue fell 30% from last quarter. Share price after the results: +11.7% in 30 days (Nifty 500: +2.4%).
Q4 FY25: Revenue ₹135 cr (+6% year on year), EBITDA ₹18.0 cr (+13% year on year), PAT ₹15.0 cr (+7% year on year), EBITDA margin 13.3% (+73 bps). Score 36 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 73 bps year on year. Profit fell 21% from last quarter. Share price after the results: −3.0% in 29 days (Nifty 500: +0.5%).
Q3 FY25: Revenue ₹123 cr (+5% year on year), EBITDA ₹24.0 cr (+9% year on year), PAT ₹19.0 cr (+12% year on year), EBITDA margin 19.5% (+71 bps). Score 33 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 71 bps year on year.
Q2 FY25: Revenue ₹110 cr (+11% year on year), EBITDA ₹14.0 cr (+100% year on year), PAT ₹12.0 cr (+71% year on year), EBITDA margin 12.7% (+566 bps). Score 83 of 100, Above trend. EBITDA margin rose 566 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Amrutanjan Health Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.